Accuray Incorporated (ARAY) : Traders are bullish on Accuray Incorporated (ARAY) as it has outperformed the S&P 500 by a wide margin of 18.16% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 12.36%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 12.54% in the last 1 week, and is up 17.53% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 13.36% and the 50-Day Moving Average is 15.85%.The 200 Day SMA reached 14.5%
Accuray Incorporated (NASDAQ:ARAY): After opening at $6.29, the stock dipped to an intraday low of $6.12 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $6.39 and the buying power remained strong till the end. The stock closed at $6.37 for the day, a gain of 2.25% for the day session. The total traded volume was 995,802. The stocks close on the previous trading day was $6.37.
Accuray Incorporated (ARAY) : The consensus price target for Accuray Incorporated (ARAY) is $10 for the short term with a standard deviation of $1.83. The most optimist securities analyst among the 4 who monitor the stock believes that the stock can reach $12, however, the pessimist price target for the company is $8.
Accuray Incorporated is a radiation oncology company. The Company develops, manufactures, sells and supports treatment solutions. Its suite of products includes the CyberKnife Systems and the TomoTherapy Systems. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy and adaptive radiation therapy. Its principal radiosurgery products, the CyberKnife Systems are robotic full-body radiosurgery system designed to treat tumors anywhere in the body non-invasively, which include the CyberKnife M6 Series with configuration options of fixed collimators plus iris variable aperture collimator, fixed collimators plus the InCise MLC and fixed collimators plus iris variable aperture collimator and the InCise MLC. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH, TomoHD and TomoHDA.